Science vs Cell: Which Journal Fits Your Life Sciences Research?

Science is a true multidisciplinary journal. It publishes research in biology, chemistry, physics, geology, engineering, medicine, and more. The editorial bar is about novelty and significance, not disciplinary fit. A breakthrough paper in systems neuroscience, genomics, chemical engineering, or climate science can all land in Science.

Cell is disciplinary: it publishes cell and molecular biology research - signaling, gene regulation, protein function, cell cycle, autophagy, cancer biology, developmental biology, and related areas. The journal does not publish ecology, organismal biology without cellular/molecular mechanism, pure computational work, or engineering unrelated to cell biology.

This is the key decision point. If your work is about cellular or molecular mechanisms, both journals could work. If it's organismal, ecological, or outside biology, Science is the only option.

Cell is particularly strong in:

• Mechanistic cell biology and signaling

• Gene regulation and transcription

• Cancer and developmental biology

• Immunology and infection biology

• Protein biochemistry and structure

Science is equally strong in those areas but also publishes:

• Organismal and evolutionary biology

• Neuroscience and behavior

• Ecology and environmental science

• Medicine and clinical research

• Chemistry and materials science

• Physics and astronomy

If your work spans multiple disciplines or is outside pure cell/molecular biology, Science is the better target.

Science looks for papers that advance understanding in any field. The story can be broad ("how do animals navigate?") or specific ("new mechanism in signaling"). As long as the work is novel and rigorous, it fits.

Cell expects papers to provide mechanistic insight into cellular processes. Descriptive work (even novel description) does not fit as well. A paper characterizing a new cell type with single-cell RNA-seq is interesting; a paper showing how that cell type exerts its function through a specific signaling pathway is Cell material. The editorial standard is "does this teach us something new about how biology works at the cellular level?"

Practical example: a study identifying a new immune cell subset with single-cell RNA-seq and showing its role across multiple organ systems could go to Science (broad biological significance). A study showing exactly how that cell subset exerts its function through a specific receptor-ligand interaction and downstream signaling cascade fits Cell better (mechanistic depth in one system).

Science journal metrics reports 5.3% for Science's research acceptance rate (2025; source checked 2026-10-21). Science journal metrics reports 8 days for Science's submission to first editorial decision (2025; source checked 2026-10-21). Science journal metrics reports 64 days for Science's submission to first post-review decision (2025; source checked 2026-10-21). Science journal metrics reports 184 days for Science's submission to acceptance (2025; source checked 2026-10-21). We have not verified comparable current Cell figures. These Science measures cover different decision outcomes; they are not a manuscript deadline or proof that one journal is faster overall.

Use this decision tree:

• Is your work primarily about cellular or molecular mechanisms? If yes, both journals could work. Proceed to step 2. If no (organismal, ecology, physics, etc.), submit to Science only.

• How broad is your story? If it's a focused mechanistic discovery, Cell. If it's broader (with or without cellular insights), Science.

• What's your field's publishing pattern? Check recent issues. Where do similar papers from your field typically publish? That's a signal of fit.

• If both fit, which are you more excited about? Pick one and submit. Both are legitimate targets.

Better fit for Cell:

• Discovery of a new signaling pathway controlling cell proliferation

• Mechanistic study of how a transcription factor regulates gene expression

• Novel CRISPR application that reveals cellular function

• Study of how a virus hijacks cellular machinery

Better fit for Science:

• New animal behavior driven by evolved neural circuits (neuroscience + behavior)

• Discovery of how climate change alters ecosystem composition

• New materials with novel properties and engineering application

• Clinical study showing a new therapeutic approach with mechanistic support

Could fit either:

• Discovery of a new immune cell function with molecular mechanistic insight

• Developmental biology study revealing a gene regulatory network

• Cancer biology study identifying a new therapeutic target

Science uses professional editors who are not active researchers. They triage fast: Science's 2025 median from submission to first decision was 8 days. The editors evaluate significance first, technical quality second. They ask: "would a reader outside this specific subfield find this interesting?" This broad appeal requirement is why Science can publish a paper on ant navigation alongside a paper on quantum computing.

Cell also uses professional PhD-level editors, but they engage more deeply with manuscripts. Cell reports a median of 10 days from submission to first decision. Cell editors sometimes consult informally with field experts before deciding. Cell's unique "revise before review" option means editors sometimes work with authors before formal peer review begins, a genuinely helpful intermediate step that does not exist at Science, Nature, or any other top journal.

Practical implication: If you submit to Cell and get a "revise before review" letter, that's a strong positive signal. It means the editor thinks the paper is worth investing in. Take the feedback seriously and revise carefully, papers that enter formal review after this step have better odds than cold submissions.

If Cell rejects citing "limited fundamental novelty" (the mechanism isn't deep enough or the biology isn't surprising) Science won't fix that. But if Cell rejects citing "scope" (the paper is interesting but not cell/molecular biology) Science is the logical next target.

If Science rejects, the reason matters. "Not broad enough" means your paper is too specialized, Cell or a field journal may be better. "Not novel enough" means the work is incremental, no top journal will take it.

Neither journal transfers to the other (different publishers). But both have internal transfer networks:

Science family: Science Advances (JIF 13.9, $5,450 base APC, gold OA), Science Translational Medicine JIF 15.6, Science Immunology JIF 16.4, Science Signaling, Science Robotics.

Cell Press family: Cell Reports (JIF 7.7, $5,790 APC), Molecular Cell JIF 16, Cell Stem Cell JIF 23.3, Cell Systems, Cell Chemical Biology.

A desk rejection from either flagship that gets transferred to a sister journal is still a strong outcome. Science Advances at IF 12.5 and Cell Reports at IF 6.9 are excellent publications.

• Your work is outside cell/molecular biology (physics, chemistry, ecology, engineering)

• The story has broad appeal beyond a single discipline

• You want a quick first editorial decision (Science's 2025 median was 8 days)

• The significance is about the finding itself, not about a cellular mechanism

• Your paper can be told in a concise format

• Your work is mechanistically complete cell or molecular biology

• The biological insight is the primary advance

• You want the "revise before review" editorial option

• Your paper needs space for dense mechanistic data (Cell research articles run under 7,000 words with no more than seven figures and/or tables; STAR Methods text and supplemental item legends do not count toward the word total)

• You're aiming within the Cell Press ecosystem long-term

A Science vs. Cell scope check can assess whether your manuscript's framing aligns with Science's broad-appeal requirement or Cell's mechanistic-depth requirement. It can prevent a misdirected 3-month review cycle.